SeQuent Scientific, Viyash Merger Gets Tribunal Nod, Combined H1 FY26 Revenue Hits ₹16,462 Million

Mumbai, November 19: SeQuent Scientific Limited (NSE: SEQUENT, BSE: 512529) has announced that the National Company Law Tribunal has approved its merger with Viyash Lifesciences. The approval was given on November 18, and the companies will now proceed with the next steps for the merger in due time. The merger is valued at ₹8,000 crore.

Strong Q2 & H1 FY26 Combined Performance

For Q2 FY26, the combined revenue for both companies stood at ₹8,521 million, marking a 16% YoY increase. EBITDA also grew to ₹1,890 million, a 76% YoY jump. The EBITDA margin increased to 22.2%, up 750 bps from last year. The company’s net debt to LTM EBITDA ratio improved to 0.7x, from 1.4x in Q2 FY25.

For the first half of FY26, combined revenue reached ₹16,462 million, increasing 12.6% YoY. EBITDA rose to ₹3,180 million, up 48% YoY. The H1 FY26 EBITDA margin was 19.3%, increasing by 460 bps. Net debt to LTM EBITDA stood at 0.7x, better than 1.4x last year.

Regulatory and Pipeline Momentum

Viyash and SeQuent collectively executed compliance, product launches and filing strongly:

• It completed 4 regulatory audits and 56 customer audits
• It received 1 US FDA EIR
• It launched two new products: 2 FDFs (US), 2 APIs.
• Its filings include: 9 across SFDA, EDQM, TGA, EDMF, WHO and Taiwan.
• It completed validations of 3 APIs

Share Price Snapshot

As of 9:32 AM, SeQuent’s share price was down by 0.13%, or 0.33 points, and was trading at ₹247.23. The traded volume stood at 24.53 lakh shares, with the company’s market cap at ₹6,262 crore. The shares of Viyash Lifesciences are not yet listed on stock exchanges.

Investor Takeaway

The merger of SeQuent Scientific with Viyash Lifesciences is a welcome step for the investors of SeQuent Scientific. The company will be able to expand by using the resources of Viyash Lifesciences and tapping into its existing customer base. The merger was approved by 99.98% of Sequent Scientific’s public shareholders, which shows that they are positive about the merger. It remains to be seen when the merger is fully executed.

REF: https://nsearchives.nseindia.com/corporate/SEQUENT1_18112025230522_SEsigned.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations